Key Proteo's ATP7B Peptide Analysis Is Resolving Wilson Disease Cases Standard Testing Missed

Wilson Disease is notoriously difficult to diagnose with certainty. Genetic testing identifies ATP7B variants in the majority of cases, but a meaningful proportion of patients receive an indeterminate result, leaving clinicians and families without a clear path forward. Two new publications demonstrate that Key Proteo’s ATP7B peptide analysis can resolve these cases.

In a study recently submitted to a prestigious journal, ATP7B peptide analysis enabled confirmation of Wilson Disease in 21 pediatric patients. For each of these patients, peptide measurement provided the objective molecular evidence needed to confirm disease, enabling timely treatment — and, in the pediatric population especially, the opportunity to intervene before irreversible copper accumulation causes lasting damage to the liver or nervous system.

A separate case series currently in press at Neurology Genetics extends this story into a different clinical setting. Three patients presenting with complex neurological symptoms — the kind that can resemble movement disorders, psychiatric illness, or other conditions entirely — had their Wilson Disease diagnosis confirmed through ATP7B peptide analysis after conventional approaches had not reached a conclusion. These findings highlight an under appreciated dimension of Wilson Disease: its neurological presentations are common, frequently delayed in diagnosis, and now demonstrably resolvable with proteomic testing.

Together, these studies add to a growing body of evidence that ATP7B peptide measurement fills a genuine diagnostic gap — not as a replacement for genetic testing, but as the confirmatory layer that closes cases conventional methods leave open. Publication details will be shared on our References page upon formal acceptance.